J Cancer 2021; 12(5):1493-1498. doi:10.7150/jca.46877

Research Paper

Clinical Evaluation of Transarterial Infusion Chemotherapy for Advanced Esophageal Cancer

Mei-Pan Yin, MD1, Peng-Fei Xie, MD1, Yue Zhao, MD1, Wei He, MD2, Yao-Zhen Ma, MD1, Chun-Xia Li, MD1, Zhen Li, MD1, Yan-Wei Zeng, MD1, Gang Wu, MD1✉

1. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
2. Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Yin MP, Xie PF, Zhao Y, He W, Ma YZ, Li CX, Li Z, Zeng YW, Wu G. Clinical Evaluation of Transarterial Infusion Chemotherapy for Advanced Esophageal Cancer. J Cancer 2021; 12(5):1493-1498. doi:10.7150/jca.46877. Available from https://www.jcancer.org/v12p1493.htm

File import instruction

Abstract

Background: Most esophageal cancer patients are diagnosed at an advanced stage when there are few effective treatments. Transarterial infusion chemotherapy is a local chemotherapy method wherein chemotherapeutic drugs are directly injected into tumor vessels.

Methods: Transarterial infusion chemotherapy was performed on advanced esophageal cancer patients once a month, and each patient underwent 1-3 treatments. The clinical results, complications, and effectiveness rates of each treatment episode were recorded and analyzed.

Results: Transarterial infusion chemotherapy was successfully performed in all patients, and no severe complications such as paraplegia or death were noted. Complete response, partial response, and stable disease were noted in 17.3% (13/75), 77.3% (58/75), and 5.3% (4/75) of cases after transarterial infusion chemotherapy, respectively. The total treatment efficacy (complete response + partial response) was 94.7%. All cases exhibited improvement in clinical stage, with a marked decrease in dysphagia. Subsequent treatments were administered to 13 patients, including radical radiation in 7 and chemotherapy in 6. During follow-up, death was caused by progressive carcinoma in 20, tumor-related pneumatic infection and respiratory failure in 11, and gastrointestinal hemorrhage in 17. The median survival time was 15 months and the 1-year survival rate was 58.1%.

Conclusions: Transarterial infusion chemotherapy may be safely and effectively used for treatment of advanced esophageal cancer.

Keywords: Esophageal cancer, Transarterial infusion chemotherapy, Complication, Interventional radiology